Posted in Class Action on May 16, 2014
Five individuals have filed a lawsuit against the manufacturer of Low-T testosterone therapy drug AndroGel. The suit has alleged that AbbVie and Abbott Laboratories concealed facts about AndroGel and serious side-effects associated with the drug.
According to the suit, the manufacturer failed to adequately research the risks of stroke or heart attack from testosterone therapy, especially in men with existing cardiovascular disease, high cholesterol, blocked arteries, diabetes, obesity and other prior heart problems.
The suit has also alleged that AbbVie and Abbott Laboratories recklessly marketed testosterone treatments in direct-to-consumer advertisements that encourage otherwise health men to seek prescription medications for “Low T” if they are experiencing any number of general symptoms, such as lack of energy, weight gain, decreased sex drive and other natural issues experienced by men as they age.
A recent study in the Journal of the American Medical Association (JAMA), suggests the risks of Low-T therapy may outweigh the benefits. Researchers reported that men who used testosterone were 30 percent more likely to have a heart attack or stroke or to die during a three-year period than men with low hormone levels who didn’t take the supplements. The study’s 3,000 participants averaged 60 years of age and most of the men (hormone users and non-users) had other health problems including high blood pressure, unhealthy cholesterol and diabetes.
If you have questions about complications from Low-T testosterone therapy, call the attorneys at Bryan & Terrill, 918-935-2777.